{"filing":{"accession_number":"0001171843-26-005824","cik":"0001114448","ticker":"NVSEF","company_name":"NOVARTIS AG","form":"6-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"f6k_090126.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1114448/000117184326005824/f6k_090126.htm"},"events":[{"id":30750,"run_id":28192,"accession_number":"0001171843-26-005824","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces positive Phase III trial results for remibrutinib (REMODEL-1/-2 trials) in relapsing multiple sclerosis, demonstrating superiority versus teriflunomide on primary and key secondary endpoints with a favorable safety profile. While the disclosure involves clinical trial progress toward a potential new indication, it does not constitute an earnings release (no financial results), executive change, M\u0026A activity, or other discrete event types. The announcement of significant clinical trial success that supports future regulatory submission and commercialization is a material operational/strategic milestone for a pharmaceutical company, warranting classification as an operational event rather than a more specific category.","company_name":"NOVARTIS AG","ticker":"NVSEF","filing_date":"2026-09-01","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":33455,"accession_number":"0001171843-26-005824","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces positive Phase III trial results for remibrutinib (REMODEL-1/-2 trials) in relapsing multiple sclerosis, demonstrating superiority versus teriflunomide on primary and key secondary endpoints with a favorable safety profile. While the disclosure involves clinical trial progress toward a potential new indication, it does not constitute an earnings release (no financial results), executive change, M\u0026A activity, or other discrete event types. The announcement of significant clinical trial success that supports future regulatory submission and commercialization is a material operational/strategic milestone for a pharmaceutical company, warranting classification as an operational event rather than a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T10:22:37.512190+00:00","company_name":"NOVARTIS AG","ticker":"NVSEF","filing_date":"2026-09-01"}]}